Pyoderma Gangrenosum

Overview

Pyoderma gangrenosum (PG) is a rare, severe, non-infectious inflammatory cutaneous disease belonging to the group of neutrophilic dermatoses. Despite its name, it is neither an infectious pyoderma nor a primary gangrenous necrosis; rather, it is driven by dysregulated innate immune activation leading to dermal neutrophilic infiltration and tissue destruction.

Characterized by rapidly expanding, excruciatingly painful cutaneous ulcers with gunmetal-colored or violaceous, undermined borders, pyoderma gangrenosum is associated with underlying systemic inflammatory diseases—such as Inflammatory Bowel Disease (IBD), inflammatory arthritis, and hematological malignancies—in approximately 50% of cases. Recognizing pyoderma gangrenosum is a critical clinical skill because surgical debridement is strictly contraindicated due to the phenomenon of pathergy.

Aetiology & Risk Factors

Systemic Associations (~50% of Patients)

Pyoderma gangrenosum frequently serves as a cutaneous manifestation of an underlying systemic autoinflammatory condition:

• Inflammatory Bowel Disease (IBD): Ulcerative Colitis (more common) and Crohn’s Disease.
• Inflammatory Arthritis: Rheumatoid Arthritis, Seronegative Spondyloarthropathies, and Ankylosing Spondylitis.
• Hematological Malignancies & Dyscrasias: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Polycythemia Vera.
• Monogenic Autoinflammatory Syndromes: PAPA syndrome (Pyogenic Arthritis, Pyoderma gangrenosum, and Acne) and PASH syndrome (Pyoderma gangrenosum, Acne, and Suppurative Hidradenitis).

Risk Factors

• Most commonly presents in adults aged 30 to 60 years.
• Triggers: Minor skin trauma, surgery, insect bites, or catheter insertion sites (via pathergy).

Pathophysiology

• Immune Dysfunction: Impaired regulation of the innate immune system leads to abnormal neutrophil chemotaxis, priming, and hyper-reactivity.
• Cytokine Cascade: Markedly elevated levels of interleukin-1 beta (IL-1$\beta$), interleukin-8 (IL-8), interleukin-17 (IL-17), and Tumor Necrosis Factor-alpha (TNF-$\alpha$) drive continuous neutrophil recruitment to the skin.
• Tissue Destruction: Neutrophils release Matrix Metalloproteinases (MMPs) and reactive oxygen species, causing local microvascular damage, tissue infarction, and rapidly spreading ulceration.

Clinical Manifestations

• Initial Lesion: Small, painful, dusky-red nodule, pustule, or blood-filled bulla that breaks down within 24 to 48 hours.
• Ulcer Features:
  • Border: Raised, violaceous (purple-gunmetal), overhang/undermined edges.
  • Base: Purulent, fibrinous, or necrotic bed with focal hemorrhagic dots.
  • Surrounding Skin: Erythematous, indurated halo expanding radially.
• Pain: Severe, excruciating pain that is strikingly disproportionate to the physical size of the lesion.
• Pathergy Sign: Lesion flares, expands rapidly, or develops new satellite ulcers following minor trauma or diagnostic procedures.

Diagnosis

Pyoderma gangrenosum is a diagnosis of exclusion. There are no specific diagnostic laboratory markers or pathognomonic histological features.

Diagnostic Criteria (PARACELSUS Score / Delphi Consensus)

Diagnosis requires ruling out other causes of cutaneous ulceration (e.g., vascular, infectious, vasculitic, or malignant etiologies).

• Major Criteria: Rapidly progressive, painful, necrotizing cutaneous ulcer with violaceous, undermined borders, and exclusion of relevant differential diagnoses.
• Minor Criteria: History of pathergy, systemic disease association (IBD/arthritis), prompt response to systemic corticosteroids, and dense neutrophilic infiltrate on skin biopsy.

Workup & Laboratory Investigations

• Skin Biopsy (Edge of Ulcer):
  • Purpose: Performed carefully at the active, advancing border to rule out vasculitis, deep fungal infections, or malignancy.
  • Histology: Demonstrates dense dermal neutrophilic infiltration and microabscesses without evidence of primary leukocytoclastic vasculitis.
• Microbiological Swabs & Tissue Cultures: Gram stain, bacterial, fungal, and atypical mycobacterial cultures to exclude primary infectious ulcers.
• Systemic Screening Workup:
  • Gastrointestinal: Colonoscopy / Sigmoidoscopy to evaluate for occult IBD.
  • Hematological: Complete Blood Count (CBC), peripheral blood smear, Serum Protein Electrophoresis (SPEP) to evaluate for leukemia, MDS, or MGUS.
  • Rheumatological: ANCA, ANA, Rheumatoid Factor, and Anti-CCP to rule out systemic vasculitis (e.g., Granulomatosis with Polyangiitis) and Rheumatoid Arthritis.

CRITICAL WARNING: Skin biopsy should be performed with extreme caution. Always take a small, precise punch sample from the active border to minimize the risk of triggering pathergy and worsening the ulcer!

Treatment

General Measures & Wound Care

• AVOID SURGICAL DEBRIDEMENT: Absolute Rule. Surgical excision, debridement, or aggressive wound scraping triggers severe pathergic expansion of the ulcer.
• Non-Adherent Dressings: Gently apply non-adherent, moist, barrier dressings to protect against secondary infection and mechanical irritation.

Pharmacotherapy

• Mild / Localized Disease:
  • Topical High-Potency Corticosteroids: Clobetasol propionate 0.05% ointment applied to the active violaceous border.
  • Topical Calcineurin Inhibitors: Tacrolimus 0.1% ointment.
• Severe / Rapidly Progressive / Extensive Disease (First-Line Systemic):
  • Systemic Corticosteroids: Oral Prednisone (1.0–2.0 mg/kg/day) or IV Methylprednisolone pulse therapy for rapid control.
  • Cyclosporine: Oral Cyclosporine (3–5 mg/kg/day) is highly effective, either as monotherapy or combined with corticosteroids.
• Refractory / Second-Line Therapy (Biologics):
  • TNF-Alpha Inhibitors: Infliximab (strongest evidence base) or Adalimumab—particularly useful in patients with co-existing Inflammatory Bowel Disease.
  • Interleukin Inhibitors: Anakinra (IL-1 inhibitor), Ustekinumab (IL-12/23 inhibitor), or Secukinumab (IL-17 inhibitor).

Complications & Prognosis

Complications

• Iatrogenic Ulcer Worsening: Rapid expansion of the wound caused by mistaken diagnosis followed by surgical debridement (a common clinical diagnostic trap!).
• Secondary Bacterial Infection: Superinfection of the open ulcer bed by Staphylococcus aureus or Pseudomonas aeruginosa.
• Severe Scarring: Extensive cribriform or hypertrophic scarring causing cosmetic disfigurement and joint contractures when crossing flexor surfaces.
• Sepsis: Rare, secondary to severe systemic bacterial invasion through extensive open wounds.

Prognosis

• The clinical course is unpredictable and highly variable. While lesions can respond rapidly to systemic immunosuppression, complete healing often takes several months.
• Prognosis is closely tied to the control of any underlying systemic disorder (e.g., controlling IBD flares often leads to remission of peristomal pyoderma gangrenosum).
• Recurrence rates reach up to 30%, frequently triggered by minor trauma or systemic disease relapse.

References

1. Su WP, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790-800. doi:10.1111/j.1365-4632.2004.02128.x
2. Maverakis E, Ma C, Shinkai K, et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol. 2018;154(4):461-466. doi:10.1001/jamadermatol.2017.5980
3. George C, Deroide F, Rustin M. Pyoderma gangrenosum – a guide to diagnosis and management. Clin Med (Lond). 2019;19(3):224-228. doi:10.7861/clinmedicine.19-3-224